Sulfotransferase 2B1 pharmacogenetics
View Patent ↗Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are sulfotransferase allozymes. Methods for determining the sulfonator status of a subject also are described. In addition, methods for predicting the therapeutic efficacy of a compound in a subject are described, as are methods for estimating the dose of a compound to be administered to a subject.
1. An isolated nucleic acid molecule consisting of:
(a) fifteen to 100 contiguous nucleotides of SEQ ID NO:11, wherein said nucleic acid molecule includes nucleotide 148 of SEQ ID NO:11, with the proviso that the nucleotide at position 148 is adenine; or
(b) the complement of (a).
2. An article of manufacture comprising a substrate, wherein said substrate comprises the isolated nucleic acid molecule of claim 1 .
3. The isolated nucleic acid of molecule of claim 1 , wherein said isolated nucleic acid molecule is 20 to 50 nucleotides in length.
4. A vector comprising the nucleic acid molecule of claim 1 .
5. The vector of claim 4 , wherein said nucleic acid molecule is 20 to 50 nucleotides in length.
6. An isolated nucleic acid molecule consisting of:
(a) fifteen to 100 contiguous nucleotides of SEQ ID NO:11, wherein said nucleic acid molecule includes nucleotide 148 of SEQ ID NO:11, with the proviso that the nucleotide at position 148 is adenine; or
(b) the complement of (a), and, with respect to (a) or (b), a label.
7. The isolated nucleic acid molecule of claim 6 , wherein said label is a fluorescent moiety.
8. The isolated nucleic acid molecule of claim 6 , wherein said label is biotin.
9. The isolated nucleic acid of molecule of claim 6 , wherein said isolated nucleic acid molecule is 20 to 50 nucleotides in length.
10. An article of manufacture comprising a substrate, wherein said substrate comprises the isolated nucleic acid molecule of claim 6 .